Study for correlation between changes in stimulatory immune checkpoints of peripheral blood lymphocyte and efficacy before and after treatment with PD-1 for advanced NSCLC patients
Not Applicable
Not yet recruiting
- Conditions
- SCLC
- Registration Number
- ITMCTR1900002416
- Lead Sponsor
- Shanxi Provincial Hospital of Traditional Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. Aged greater than or equal to 18 years;
2. Histopathology is clearly diagnosed as NSCLC;
3. Clinical stage is stage IV;
4. ECOG score is 0 to 2 points;
5. There are evaluable lesions.
Exclusion Criteria
1. There have been acute cardiogenic diseases or chronic basic diseases, which may interfere with treatment after evaluation;
2. previous severe liver and kidney dysfunction;
3. end stage, inability to tolerate PD-1 treatment;
4. patients autoimmune system disease.
Study & Design
- Study Type
- Basic Science
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link stimulatory immune checkpoint changes to PD-1 efficacy in advanced NSCLC?
How does PD-1 therapy alter peripheral blood lymphocyte checkpoint expression in SCLC patients compared to standard treatments?
Which biomarkers correlate with PD-1 treatment response in advanced NSCLC through immune checkpoint modulation?
What adverse events are associated with PD-1-induced immune checkpoint changes in peripheral blood lymphocytes for SCLC?
Are there combination therapies enhancing PD-1 efficacy by modulating stimulatory immune checkpoints in advanced NSCLC?